
Experts Outline Safety Guidelines for Fully Ablative Lasers
Published in the June 2025 issue of Lasers in Surgery and Medicine , the consensus statement brings together expert recommendations on how to prevent and manage complications related to fully ablative laser resurfacing of the face. The authors emphasize that, while individual practice styles vary, consistent themes emerged — highlighting the importance of patient selection, comprehensive counseling, and detailed pre- and postprocedural care to improve safety and outcomes.
Why This Matters
Fully ablative carbon dioxide and erbium-doped yttrium aluminum garnet lasers remain gold standards for treating photodamaged skin because of their ability to provide deep resurfacing and robust collagen remodeling. But these benefits come at a cost: More extensive skin injury and a higher risk for complications compared with fractional or nonablative lasers, according to the authors.
Arisa Ortiz, MD
Risks include prolonged erythema, infection, pigmentary alterations, and scarring — issues that can be distressing to patients and difficult to manage without a standardized care framework. The consensus authors emphasized that, until now, clinical protocols for the prevention and management of complications have been largely based on anecdotal and variable experience.
Asked to comment on the consensus statement, one of the consensus authors, Arisa Ortiz, MD, dermatologist and director of Laser and Cosmetic Dermatology at UC San Diego Health, San Diego, called the statement 'a landmark in laser dermatology.'
'This consensus is a landmark in laser dermatology, finally providing unified, expert-backed guidance for a procedure that has historically lacked standardization. It gives clinicians a clear, practical roadmap for safe and effective fully ablative resurfacing,' Ortiz said.
Pooja Sodha, MD
Pooja Sodha, MD, associate professor of dermatology at George Washington School of Medicine & Health Sciences and director of the Center for Laser and Cosmetic Dermatology, both in Washington, DC, agreed with this sentiment, emphasizing the document is especially useful in clinical practice. 'This consensus helps to organize the thought process of how to prepare, counsel, and treat patients, almost providing a step-by-step guide of items to consider. This is great for new and old practitioners,' Sodha told Medscape Medical News . She was not an author of the statement.
Key Recommendations
The consensus outlines detailed step-by-step strategies to help clinicians reduce the risk for complications following fully ablative laser resurfacing. These recommendations span the entire patient journey — from pretreatment counseling to postoperative monitoring and management of adverse effects:
Infection prevention. The authors recommend antiviral prophylaxis for all patients undergoing full-face resurfacing, even when treatment is limited to perioral or periocular areas. 'The preferred agent for antiviral prophylaxis is valacyclovir, unless otherwise indicated,' they wrote. The consensus group also noted that oral or topical antibacterial prophylaxis may be appropriate in higher-risk individuals, such as those with diabetes or a history of methicillin-resistant Staphylococcus aureus colonization.
The authors recommend antiviral prophylaxis for all patients undergoing full-face resurfacing, even when treatment is limited to perioral or periocular areas. 'The preferred agent for antiviral prophylaxis is valacyclovir, unless otherwise indicated,' they wrote. The consensus group also noted that oral or topical antibacterial prophylaxis may be appropriate in higher-risk individuals, such as those with diabetes or a history of methicillin-resistant colonization. Postprocedural wound care. The authors emphasized the importance of frequent cleansing with soaks and keeping the skin moist with emollients. 'It is beneficial to apply topical lanolin‐free ointment or other appropriate posttreatment topical product,' the group noted.
The authors emphasized the importance of frequent cleansing with soaks and keeping the skin moist with emollients. 'It is beneficial to apply topical lanolin‐free ointment or other appropriate posttreatment topical product,' the group noted. Early recognition of infection. Patients should be educated to report signs such as increasing pain, drainage, erythema, or fever. 'It is appropriate to promptly evaluate (in person or virtually) patients with signs or symptoms concerning for infection,' the authors wrote.
Patients should be educated to report signs such as increasing pain, drainage, erythema, or fever. 'It is appropriate to promptly evaluate (in person or virtually) patients with signs or symptoms concerning for infection,' the authors wrote. Addressing pigmentary changes. The authors note that pigmentary changes such as hyperpigmentation, a common postprocedural complication, often resolve over 6-12 months, but proactive management may improve outcomes. The panel supports the use of 'topical lightening or bleaching agents' as helpful for treating hyperpigmentation and considers laser-based interventions or oral tranexamic acid in select patients, provided clotting risks are ruled out.
The authors note that pigmentary changes such as hyperpigmentation, a common postprocedural complication, often resolve over 6-12 months, but proactive management may improve outcomes. The panel supports the use of 'topical lightening or bleaching agents' as helpful for treating hyperpigmentation and considers laser-based interventions or oral tranexamic acid in select patients, provided clotting risks are ruled out. Scarring management. The consensus group recommended addressing scarring at the earliest signs. Interventions include intralesional corticosteroids or 5-fluorouracil, vascular lasers, or 'laser-assisted drug delivery of corticosteroid and/or 5‐fluorouracil,' according to the authors.
Challenges and Controversies
While the consensus process produced strong agreement in many areas, some topics remained divisive. Only a subset of proposed adverse events and contraindications reached full consensus. For instance, pretreatment counseling about eruptive keratoacanthomas or milia as possible adverse events did not meet agreement thresholds, according to the authors.
Ortiz noted that disagreement over rare complications reflects the complexity of real-world care. 'While most statements achieved strong agreement, there were important areas — like counseling for rare complications or defining contraindications — where expert opinions diverged,' she explained. 'These gray zones underscore the need for continued discussion and individualized care.'
The risk for vitiligo induction after laser resurfacing is still under debate. While not a formal contraindication, the authors suggest that 'practitioners might consider incorporating family history assessments into pretreatment consultations.'
The panel also noted that while darker Fitzpatrick skin types are not a contraindication to fully ablative laser resurfacing of the face, these patients face higher risks for postinflammatory pigmentary changes. Providers should employ strategies to reduce risk, which include conservative settings, rigorous sun protection, and topical corticosteroids after treatment when appropriate, according to the consensus group.
Sodha emphasized this point as an important area for ongoing refinement: 'I believe this statement is important — 'Darker Fitzpatrick skin types were not considered a contraindication to treatment' — and it highlights that our settings in this population need to be adjusted and these patients need to be counseled on the pigmentary risks, but treatment is still possible,' she explained. 'Building continued comfort here and defining the right parameters is worthy of a little more consideration in future guideline development.'
Sodha also noted that although the recommendations may seem straightforward, successful integration takes practice. 'The steps themselves are not difficult. This is about common sense,' she said. 'These recommendations remind us how important repetition is in integrating these principles so they are second nature.'
Looking Ahead
This expert-driven consensus offers a foundation for safe and consistent care in laser resurfacing but also highlights areas for future research, according to the authors.
Ortiz told Medscape Medical News that future data will be essential to address gaps in evidence. 'There's a pressing need for high-quality studies focused on managing complications like hypopigmentation and scarring, particularly to better understand long-term pigmentary outcomes and optimize treatment safety across diverse populations.'
The study received no specific funding. Several authors disclosed financial relationships with industry, while Ortiz and Podha reported no relevant disclosures.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Health Line
3 hours ago
- Health Line
What Are the Health Benefits of Laughter?
When you laugh, your body responds in ways that promote healing, relaxation, and resilience. Laughter is more than a spontaneous reaction to something funny. It's a natural and powerful tool that can support your physical and mental well-being. Whether you're watching a comedy special, sharing a joke with a friend, or laughing at your own mistakes, the simple act of laughing can provide meaningful health benefits that go far beyond the moment. Boosts immunity Laughter has been shown to reduce stress hormones like cortisol and increase immune cells and infection-fighting antibodies. This strengthens your immune response and helps protect you from illness. Even a few minutes of genuine laughter can stimulate changes in immune activity that make your body more resistant to disease. Enhances cardiovascular function Laughter improves the function of blood vessels and increases blood flow, which can help reduce your risk of heart conditions. When you laugh, your heart rate rises briefly, followed by a period of muscle relaxation and decreased blood pressure. This mirrors the effects of light physical activity and supports better circulation throughout your body. Relieves physical tension and pain Laughter stimulates the release of endorphins, which are your body's natural feel-good chemicals. Endorphins not only enhance your mood but also act as natural pain relievers. Regular laughter can reduce the perception of pain and increase your tolerance to discomfort. Physically, it also relaxes your muscles, relieving tension long after you've stopped laughing. Supports respiratory health When you laugh deeply, you engage your diaphragm and lungs, stimulating oxygen intake and clearing stale air from your lungs. This can be especially beneficial if you spend long periods sitting or taking shallow breaths due to stress or inactivity. A hearty laugh helps you take in oxygen and promotes a more open airway, making it easier to breathe. Provides a light physical workout Laughing can stimulate many of the same systems activated during physical activity. It engages your abdominal muscles, shoulders, and diaphragm and can even increase your heart rate. While it won't replace a gym session, a bout of laughter can give your body a small workout and support physical activity in a gentle and enjoyable way. Reduces stress and anxiety Laughter reduces the levels of stress hormones in your body and increases the production of calming neurochemicals like dopamine and serotonin. These changes can shift your mindset and reduce the mental and emotional weight of stress and anxiety. Laughing during challenging situations helps you gain perspective and feel more grounded, even if the circumstances haven't changed. Improves mood When you laugh, you feel lighter, happier, and more present. That mood lift isn't just temporary — it can help reduce symptoms of depression and increase your sense of life satisfaction. Shared laughter can also deepen connection to others, reinforcing your support network and boosting emotional resilience. Strengthens relationships Laughter fosters closeness and trust in relationships. Sharing a genuine laugh with someone builds emotional bonds and encourages openness and vulnerability. Whether you're laughing with a partner, friend, co-worker, or family member, humor can defuse tension, resolve conflict, and promote empathy. These social connections are vital for your long-term mental health and well-being. Enhances cognitive function Positive emotions, such as those triggered by laughter, can sharpen focus and improve memory. Laughter also encourages mental flexibility and creativity. Laughter reduces stress and increases psychological safety, which can help you approach challenges with a clearer, more adaptive mindset. Promotes emotional resilience When you develop the habit of finding humor in daily life, you build resilience. Laughter helps you stay hopeful and optimistic, even during setbacks. It reminds you that joy and difficulty can exist side by side and gives you a way to cope without feeling overwhelmed. Even when you don't feel like laughing, the act of smiling or watching something amusing can lead to real laughter. Over time, this practice becomes easier and more natural, and the benefits become more pronounced.

Wall Street Journal
7 hours ago
- Wall Street Journal
Here's How Quantum Computing Could Change the World
With commercial grade quantum computers inching closer to reality, industries are already investigating their impact on everything, from food to medicine to streaming football games. Quantum computers are expected to power certain computations that would take today's conventional computers years to solve, if they could at all.
Yahoo
9 hours ago
- Yahoo
Anavex's blarcasemine nets win in Phase IIb/III Alzheimer's extension study
In another potential win for patients with early-stage Alzheimer's disease, Anavex Life Science's precision medicine blarcasemine has met its primary endpoints in a late-stage trial. Announced at the 2025 Alzheimer's Association International Conference (AAIC), results of the Phase IIb/III ATTENTION-AD (NCT04314934) extension study revealed that blarcasemine, dubbed internally as Anavex 2-73, improved patients' cognitive function by 36.3%, as measured by the Alzheimer's Disease Assessment Scale-Cognitive 13-item (ADAS-COG13) scale. The oral autophagy reactivator also improved daily functioning by 27.6% according to the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) scale, highlighting the drug's capacity to stave off symptoms of Alzheimer's in the disease's early stages. Like other Alzheimer's-targeting disease modifying therapies (DMTs) on the market, blarcasemine worked best in patients who began taking the drug early, with early initiation offering patients 19.5 months of 'time saved'. The 'time saved' concept describes the period in which a drug can stave off disease progression and allow patients to maintain both functionality and independence. Alzheimer's market competition heats up In recent years, the once stagnant Alzheimer's market has been ignited — primarily driven by the approvals of key anti-amyloid beta monoclonal antibodies (Aβ mAbs) such as Biogen & Eisai's Leqembi (lecanemab) and Eli Lilly's Kisunla (donanemab), which were given FDA greenlights in 2023 and 2024, respectively. This has driven the market's value significantly, with a forecast from GlobalData, parent company of Clinical Trials Arena, estimating it will be worth $19.3bn in the 8 major markets (8MM includes the US, Germany, France, Italy, Spain, the UK, Japan and China) by 2033. According to a report by Globaldata, these therapies are set to dominate the Alzheimer's market, with Kisunla and Leqembi forecasted to rake in $2bn and $3.5bn, respectively, in the 8MMs. However, neurology analyst at GlobalData, Phillipa Salter noted that anti-Aβ mAbs have been difficult to integrate into clinical practice due to 'their association with significant side effects, including amyloid-related imaging abnormalities (ARIA).' 'They are also only modestly effective, so having alternative treatment options that don't target amyloid will be welcomed in the AD space,' Salter commented. Salter added: 'Significant opportunity therefore exists for Anavex 2-73 with its convenient oral dosing and favourable safety profile.' Instead of targeting and breaking down tau and beta amyloid (Aβ) plaques like Kisunla and Leqembi, Anavex 2-73 works to restore cellular autophagy — a natural process which becomes faulty in early Alzheimer's disease pathology before plaques begin to form. By targeting a mechanism involved in the very early stages of Alzheimer's, blarcasemine differentiates itself from rival therapies at market. "Anavex's blarcasemine nets win in Phase IIb/III Alzheimer's extension study" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio